• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 482999 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1417209700 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1417209700 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Keryx Biopharmaceuticals Makes a Move: Up 2.2%

Published on Fri, 04/19/2013 - 12:25
By Robert Cotter

Keryx Biopharmaceuticals (NASDAQ:KERX) is one of today's biggest movers, up 2.2% to $7.78. The S&P is trading higher by 0.5% to 1,550 and the Dow is trading 0.3% lower to 14,499.

In the past 52 weeks, shares of Keryx Biopharmaceuticals have traded between a low of $1.28 and a high of $9.98 and are now at $7.78, which is 508% above that low price. Over the past week, the 200-day moving average (MA) has gone up 3.2% while the 50-day MA has advanced 0.3%.

Keryx Biopharmaceuticals (NASDAQ:KERX) has potential upside of 65.3% based on a current price of $7.78 and analysts' consensus price target of $12.86. The stock should find initial support at its 50-day moving average (MA) of $7.14 and further support at its 200-day MA of $3.82.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinold compound for the treatment of diabetic nephropathy.

By Robert Cotter
rcotter@fnno.com

Latest News from FNNO

Shares of ConAgra Foods Rise Above Previ...

Shares of ConAgra Foods (NYSE:CAG) traded at a new 52-week high today of $36.58. So fa ...

CACI International: 52-Week High Recentl...

Shares of CACI International (NASDAQ:CACI) traded today at $90.11, breaking its 52-week ...

Watch for Continued Gains in Shares of B...

Boston Properties (NYSE:BXP) traded today at a new 52-week high of $131.15. This new h ...

Brown Shoe Looks to Continue to Trade Ab...

Shares of Brown Shoe (NYSE:BWS) traded at a new 52-week high today of $33.61. This new ...

Buffalo Wild Wings: 52-Week High Recentl...

Buffalo Wild Wings (NASDAQ:BWLD) traded today at a new 52-week high of $171.06. So far ...

Shares of Anheuser-Busch InBev Rise to a...

Anheuser-Busch InBev (NYSE:BUD) traded today at a new 52-week high of $117.47. Approxi ...

Watch for Continued Losses in Shares of ...

Shares of Baytex Energy Trust (NYSE:BTE) traded today at $21.63, breaking its 52-week l ...

Watch for Continued Gains in Shares of B...

Shares of Berkshire Hathaway (NYSE:BRK.B) traded today at $149.49, breaking its 52-week ...